Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan To Cut Drug Prices in April

This article was originally published in PharmAsia News

Executive Summary

TOKYO - In the beginning of March, Japan's Ministry of Health, Labour and Welfare plans to release a full list of drugs that will be repriced starting in April. The average price cut is expected to be roughly 5.2 percent and includes top-selling prescription drugs

You may also be interested in...



Japan To Lower Price Of Eight Drugs From Takeda, Novartis, BMS And Chugai By 12-18 Percent

As part of an ongoing re-pricing policy for drugs that have seen expanded market share, Japan's Ministry of Health, Labor and Welfare has decided to lower the price on eight drugs effective April 1

Japan To Lower Price Of Eight Drugs From Takeda, Novartis, BMS And Chugai By 12-18 Percent

As part of an ongoing re-pricing policy for drugs that have seen expanded market share, Japan's Ministry of Health, Labor and Welfare has decided to lower the price on eight drugs effective April 1

Japan's Medical Insurance Agency Considers Lowering Combo Drug Prices

Japan's Drug Pricing Committee of the Central Medical Insurance Agency [Chuikyo] considered a proposal July 15 to revise the current pricing formula for combination drugs, and some angiotensin II receptor blockers combined with diuretics could see prices lowered by as much as 30 percent in Japan

Related Content

UsernamePublicRestriction

Register

PS140995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel